Uniunea Europeană - estoniană - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastilised ained - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patsientidel, kellel on madal või väga madal risk kordumise ei tohiks saada abiaine ravi. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Estonia - estoniană - Ravimiamet

tad pharma gmbh - dabigatraaneteksilaat - kõvakapsel - 75mg 180tk; 75mg 100tk; 75mg 60tk

Estonia - estoniană - Ravimiamet

g.l. pharma gmbh - bromasepaam - õhukese polümeerikattega tablett - 3mg 30tk; 3mg 20tk

Estonia - estoniană - Ravimiamet

g.l. pharma gmbh - pregabaliin - kõvakapsel - 50mg 20tk; 50mg 120tk; 50mg 60tk; 50mg 21tk; 50mg 200tk; 50mg 30tk; 50mg 100tk; 50mg 112tk; 50mg 28tk; 50mg 56tk; 50mg 90tk

Estonia - estoniană - Ravimiamet

woerwag pharma gmbh & co. kg - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 150mg 10tk; 150mg 7tk; 150mg 100tk; 150mg 20tk; 150mg 56tk; 150mg 60tk; 150mg 30tk; 150mg 14tk

Estonia - estoniană - Ravimiamet

g.l. pharma gmbh - pregabaliin - kõvakapsel - 75mg 90tk; 75mg 28tk; 75mg 200tk; 75mg 60tk; 75mg 70tk; 75mg 120tk; 75mg 10tk; 75mg 56tk; 75mg 30tk; 75mg 84tk; 75mg 20tk

Estonia - estoniană - Ravimiamet

g.l. pharma gmbh - bromasepaam - õhukese polümeerikattega tablett - 6mg 20tk; 6mg 30tk

Estonia - estoniană - Ravimiamet

woerwag pharma gmbh & co. kg - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 75mg 56tk; 75mg 20tk; 75mg 60tk; 75mg 100tk; 75mg 50tk; 75mg 14tk; 75mg 10tk; 75mg 30tk; 75mg 7tk; 75mg 28tk

Estonia - estoniană - Ravimiamet

g.l. pharma gmbh - pregabaliin - kõvakapsel - 150mg 20tk; 150mg 84tk; 150mg 30tk; 150mg 60tk; 150mg 56tk; 150mg 112tk; 150mg 28tk; 150mg 200tk; 150mg 90tk; 150mg 10tk; 150mg 100tk

Estonia - estoniană - Ravimiamet

g.l. pharma gmbh - pregabaliin - kõvakapsel - 25mg 14tk; 25mg 120tk; 25mg 56tk; 25mg 28tk; 25mg 60tk; 25mg 10tk; 25mg 30tk; 25mg 84tk; 25mg 20tk; 25mg 100tk